In a report released today, Sean Wieland from Piper Jaffray reiterated a Buy rating on Tabula Rasa HealthCare (NASDAQ: TRHC), with a price target of $71. The company’s shares closed yesterday at $61.01.
According to TipRanks.com, Wieland is a top 100 analyst with an average return of 27.5% and a 71.8% success rate. Wieland covers the Technology sector, focusing on stocks such as Medidata Solutions, Quality Systems, and Athenahealth.
Currently, the analyst consensus on Tabula Rasa HealthCare is a Strong Buy with an average price target of $65.75, a 7.8% upside from current levels. In a report released yesterday, Oppenheimer also assigned a Buy rating to the stock with a $65 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $70.15 and a one-year low of $16.72. Currently, Tabula Rasa HealthCare has an average volume of 338.7K.
Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tabula Rasa Healthcare, Inc. engages in the development of pharmaceutical software that optimizes medication regimens. It offers cloud-based applications, such as EireneRx and MedWise Advisor. The company was founded by Calvin H. Knowlton and Orsula V. Knowlton in April 2009 and is headquartered in Moorestown, NJ.
